

March 11, 2024



## Chromocell to Present at Sidoti Virtual Investor Conference March 13-14

AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. ("Chromocell", or the "Company"), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced Frank Knuettel, CEO, will present and host one-on-one meetings with investors at the Sidoti March Virtual Investor Conference, taking place on March 13-14, 2024.

Chromocell's presentation will begin March 13 at 2:30-3:00 PM in Track 3 and can be accessed live here: [https://sidoti.zoom.us/webinar/register/WN\\_D2qavsKxRjOQeRIFjjLw7A](https://sidoti.zoom.us/webinar/register/WN_D2qavsKxRjOQeRIFjjLw7A).

The Company will also host virtual one-on-ones with investors on Wednesday and Thursday, March 13-14, 2024. To register for the presentation or one-on-ones, visit [www.sidoti.com/events](http://www.sidoti.com/events). Registration is free and you don't need to be a Sidoti client.

### **About Sidoti Events, LLC ("Events") and Sidoti & Company, LLC ("Sidoti")**

In 2023, Sidoti & Company, LLC, [Sidoti & Company, LLC \(www.sidoti.com\)](http://www.sidoti.com) formed a sister company, Sidoti Events, LLC in order to focus exclusively on its rapidly growing conference business and to more directly serve the needs of presenters and attendees. The relationship allows Events to draw on the nearly 25 years of experience Sidoti has as a premier provider of independent securities research focused specifically on small and microcap companies and the institutions that invest in their securities, with most of its coverage in the \$200 million-\$5 billion market cap range. Sidoti's coverage universe comprises approximately 160 equities, of which 40 percent participate in the firm's rapidly growing Company Sponsored Research ("CSR") program. Events is a leading provider of corporate access through the eight investor conferences it hosts each year. By virtue of its direct ties to Sidoti, Events benefits from Sidoti's small- and microcap-focused nationwide sales force, which has connections with approximately 1,500 institutional relationships in North America. This enables Events to provide multiple forums for meaningful interaction for small and microcap issuers and investors specifically interested in companies in the sector.

### **About Chromocell Therapeutics Corp.**

Chromocell Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive, therapeutics to alleviate pain and other associated medical conditions. The Company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes and the Company intends to explore these and other compounds for the treatment of additional pain indications. For

company updates and to learn more about Chromocell, visit [www.chromocell.com](http://www.chromocell.com) or follow us on social media.

### **Forward-Looking Statements**

This press release contains forward-looking statements regarding the Company's current expectations. These forward-looking statements include, without limitation, references to the Company's expectations regarding the closing of the public offering and its anticipated use of net proceeds from the offering. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the satisfaction of customary closing conditions related to the public offering, or factors that result in changes to the Company's anticipated use of proceeds. These and other risks and uncertainties are described more fully in the section captioned "Risk Factors" in the Company's Registration Statement on Form S-1 related to the public offering (SEC File No. 333-269188). Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

Chromocell Media and Investor Inquiries:

**LR Advisors LLC.**  
**Jason Assad**  
**678-570-6791**  
**Jason@Chromocell.com**



Source: Chromocell Corporation